Live Breaking News & Updates on Madrigal pharmaceuticals price performance

Stay updated with breaking news from Madrigal pharmaceuticals price performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bain Capital Life Sciences Investors LLC Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Bain Capital Life Sciences Investors LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 324,619 shares of the biopharmaceutical company’s stock, valued at approximately $75,110,000. Madrigal Pharmaceuticals comprises approximately […] ....

United-states , America , Roberte-waltermire , Madrigal-pharmaceuticals-inc , Citigroup , Madrigal-pharmaceuticals , Bain-capital-life-sciences-investors , Quarter-for-madrigal-pharmaceuticals , Artisan-partners-limited-partnership , Nasdaq , Vanguard-group-inc

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by StockNews.com to "Sell"

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […] ....

New-york , United-states , Piper-sandler , Roberte-waltermire , Madrigal-pharmaceuticals-inc , York-state-common-retirement-fund , Madrigal-pharmaceuticals , Analyst-recommendations-for-madrigal-pharmaceuticals , Citigroup , Charles-schwab-investment-management-inc , Canaccord-genuity-group , News-ratings-for-madrigal-pharmaceuticals-daily

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by StockNews.com to "Sell"

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […] ....

New-york , United-states , Roberte-waltermire , Piper-sandler , Canaccord-genuity-group , Citigroup , Charles-schwab-investment-management-inc , Madrigal-pharmaceuticals-company-profile , Hedge-funds-weigh-in-on-madrigal-pharmaceuticals , Jump-financial , Jp-morgan-private-wealth-advisors , Securities-exchange-commission

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $356.73 Consensus PT from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $356.73 Consensus PT from Analysts
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Switzerland , United-states , Swiss , Jamesm-daly , Rebecca-taub , Analyst-recommendations-for-madrigal-pharmaceuticals , Proshare-advisors , Oppenheimer-co , Securities-exchange-commission , News-ratings-for-madrigal-pharmaceuticals-daily , Russell-investments-group-ltd , Madrigal-pharmaceuticals

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Expectations By $1.32 EPS

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Expectations By $1.32 EPS
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United-states , Jamesm-daly , Richards-levy , Madrigal-pharmaceuticals , Madrigal-pharmaceuticals-price-performance , Madrigal-pharmaceuticals-company-profile , Earnings-history-for-madrigal-pharmaceuticals , Citigroup , Madrigal-pharmaceuticals-inc , Securities-exchange-commission , Canaccord-genuity-group